Abstract
Background
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) causes considerable hemodynamic, respiratory, and metabolic changes during the perioperative period.
Objectives
To evaluate metabolic changes associated with this procedure. Understanding perioperative factors and their association with morbidity may improve the perioperative management of patients undergoing this treatment.
Methods
A retrospective review of a prospectively maintained database was performed. All consecutive unselected patients who underwent CRS plus HIPEC between January 2018 and December 2020 (n = 219) were included.
Results
The mean age was 58 ± 11.7 years and 167 (76.3%) were female. The most frequent histology diagnosis was serous ovarian carcinoma 49.3% (n = 108) and colon carcinoma 36.1% (n = 79). Mean peritoneal cancer index was 14.07 ± 10.47. There were significant variations in pH, lactic acid, sodium, potassium, glycemia, bicarbonate, excess bases, and temperature (p < 0.05) between the pre-HIPEC and post-HIPEC periods. The closed HIPEC technique resulted in higher levels of temperature than the open technique (p < 0.05). Age, potassium level post-HIPEC potassium level, and pre-HIPEC glycemia were identified as prognostic factors for morbidity in multivariate analysis.
Conclusion
The administration of HIPEC after CRS causes significant changes in internal homeostasis. Although the closed technique causes a greater increase in temperature, it is not related to higher morbidity rates. The patient’s age, post-HIPEC potassium level, and pre-HIPEC glycemia are predictive factors for morbidity.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Peritoneal carcinomatosis (PC) is an advanced manifestation of several malignancies related to unfavorable prognosis [1]. The introduction of cytoreductive surgery (CRS) plus the administration of hyperthermic intraperitoneal chemotherapy (HIPEC) has improved the prognosis of these patients [2,3,4,5].
CRS-HIPEC has proven to be an effective therapy for malignant tumors to enhance drug delivery in the peritoneal surface after CRS, which may help to eliminate microscopic peritoneal disease [6,7,8,9,10,11,12,13]. The local administration of chemotherapy increases the concentration of cytotoxic agents without systemic toxicity associated [14].
CRS consists of a major intervention that combines peritonectomy procedures and multi-visceral resections to remove all macroscopic tumors from the peritoneal cavity. It is a complex procedure associated with similar morbidity rates to types of major surgeries [15, 16]. During the CRS, the patients develop major changes in the cardiovascular and respiratory systems, requiring specialized anesthetic and surgical management [17]. The hydroelectrolytic and metabolic alterations associated with CRS-HIPEC have been previously reported; however, these studies had a small sample size and did not clarify the effect of these homeostatic modifications on the perioperative outcomes [18,19,20,21,22].
This study aimed to analyze the intraoperative metabolic changes associated with HIPEC administration and their impact on postoperative morbidity in those patients treated with CRS-HIPEC.
Methods
A retrospective review of a prospectively maintained database was performed. All consecutive unselected patients who underwent CRS plus HIPEC between January 2018 and December 2020 (n = 219) were included. The study protocol was approved by Reina Sofia University Hospital Committee for Ethics and Research Cod: 4983 of February 2021.
Selection of patients for the CRS-HIPEC procedure
All patients included were treated according to the institutionally approved multidisciplinary protocol. Sign-informed consent was obtained. The indications of CRS-HIPEC were as follows: peritoneal carcinomatosis of primary and recurrent ovarian origin FIGO IIIc or IV underwent upfront or interval surgery (when downstaging was confirmed after neoadjuvant treatment), colorectal origin, pseudomyxoma peritonei (PMP), and malignant mesothelioma. Infrequent indications such as carcinomatosis from the endometrial origin, sarcomatosis, gastric cancer, or GISTosis were previously evaluated by the multidisciplinary tumors committee.
The patients included had a good functional status (ECOG) of 0–2. Relative contraindications were age > 70 and body mass index (BMI) > 35 kg/m2. Patients considered suitable for CRS + HIPEC who presented relative contraindications were evaluated individually by a multidisciplinary board.
Surgical procedure
The extent of peritoneal disease was classified using the peritoneal cancer index (PCI) [23]. The principles of cytoreductive surgery and HIPEC have been previously described by Sugarbaker PH [6, 7]. After cytoreduction, HIPEC was administered using two alternative techniques: open (coliseum), which consists of suspending the entire abdominal wall and maintaining a cavity as deep as possible for the administration of HIPEC, or closed technique, which consists of filling the closed abdominal cavity with control to indicate the intra-abdominal volume and is complemented with an intra-abdominal CO2 perfusion system to improve the distribution of the HIPEC agent [24]. HIPEC was administered at 41–43 °C temperature. The chemotherapy agents employed were mitomycin C (30 mg/m2) for carcinomatosis of intestinal and appendicular origin; paclitaxel (120 mg/m2) for gynecological origin; and cisplatin plus doxorubicin (100 mg + 30 mg/m2) for peritoneal mesothelioma, sarcoma, and gastric origins. The intraperitoneal solution used for HIPEC was a 1.5% dextrose dilution (4000 mL). The flow rate employed was between 500 and 1000 mL/min. The use of ureteral catheters has been relegated since 2016, and it was used for exceptional cases such as parametria infiltration, previous complex pelvic surgery, or preoperative hydronephrosis [22].
Intraoperative anesthetic management
Patients were monitored in a standardized protocol for major surgery through ECG (electrocardiogram), NIBP (non-invasive blood pressure), and pulse oximetry before induction. Whenever there was no contraindication, an epidural catheter was placed for a combination of intra and postoperative locoregional anesthesia. Anesthetic depth was monitored using Sendline (Massimo ®). Core body temperature was monitored using an esophageal catheter. Bladder catheterization was performed to quantify urinary output. Finally, arterial and central venous lines were catheterized with ultrasound assistance. During the intervention, a minimally invasive hemodynamic monitor (MostCare Up ®, Vigileo-Flotrac®) was used with a focus on HF (Cardiac Index), PVC (central venous pressure), and PPV (pulse pressure variation) and SVV (variation stroke volume) for upcoming goal-guided fluid delivery [25].
Variables
Demographic characteristics included the following: patient’s age (years), sex, previous tobacco and alcohol consumption, diabetes mellitus, hypertension, body mass index (BMI), renal function, heart disease, and ASA score. Data tumor-related were the origin of the primary tumor and neoadjuvant chemotherapy received. Intraoperative variables included operative time (min), crystalloids and colloids administered (mL), blood products and vasoactive amine administration, diuresis, chemotherapy agent used for HIPEC, type of HIPEC technique, HIPEC (closed/open), and pre- and post-HIPEC core body temperature (°C). Intraoperative diuresis was classified as (i) < 100 mL during intervention despite diuretic administration, (ii) diuresis forced by diuretics, and (iii) spontaneous diuresis.
Surgical procedure data included PCI, multi-visceral or intestinal resections, and CC score (Sugarbaker’s completeness of cytoreduction score) [26]. Optimal cytoreduction was defined as a CC score of 0–1 since the HIPEC tissue penetration is considered around 2–3 mm. The extension of the peritonectomy procedure was classified according to Sugarbaker’s description: 1–3 regions (partial), 4–6 regions (extended), and more than 6 regions (total) [2].
Pre and post-HIPEC variables: immediately before the start of HIPEC, a blood sample was taken from the patient. At the end of HIPEC, an additional blood sample was obtained to evaluate the homeostatic imbalance caused by HIPEC. The level of pH, lactic acid (mmol/L), excess of base (mmol/L), bicarbonate (mmol/L), sodium (mmol/L), potassium (mmol/L), and glucose (mg/dL) levels were examined on portable blood analyzers (GEM PREMIER 4000 — Werfen ®) in the operating room.
Postoperative outcomes included 30- and 90-day morbidity (Dindo-Clavien classification) [27, 28], hospital length stay (days), and recurrence rate (%). Major morbidity was defined as Dindo-Clavien grade ≥ 3.
Statistical analysis
Categorical variables were expressed as total numbers and percentages and were compared using a Chi-square or Fisher’s exact test. Continuous data were expressed as means ± standard deviation and were compared using Student’s t, Mann Whitney U, Welch, or ANOVA tests, according to the distribution of data. Statistical significance was set at p < 0.05.
Logistic regression models were performed considering early major complications Dindo-Clavien ≥ 3 (< 30 days) as a dependent variable. All preoperative and intraoperative variables were analyzed as independent variables by univariate analysis, selecting those with p < 0.15 for the multivariate analysis. Subsequently, with the selected variables, a multiple logistic regression analysis was performed using the Wald test, and the variables with a p < 0.15 (methodical backward selection procedure) were included in the larger model and one by one eliminated from the model. The variables with significance greater than 0.05 were reviewed as possible confounding factors considering them as such if the percentage of change in the coefficients was greater than 15%. As a logistic test for extreme cases, Cook’s distance was used. The Hosmer–Lemeshow statistic based on percentiles was used to assess goodness of fit. SPSS 22.0 (SPSS, Chicago, IL®).
Results
Between January 2018 and December 2020, a total of 219 patients were undergone CRS + HIPEC. The preoperative demographic parameters are described in Table 1. The mean age was 58 ± 11.7 years and 167 (76.3%) were female. One hundred thirty-eight (62.9%) patients had overweight-obesity. Tumor histologic origins were serous ovarian carcinoma 49.3% (n = 108), colorectal 36.1% (n = 79), peritoneal pseudomyxoma 7.8% (n = 17), endometrium 2.7% (n = 6), peritoneal mesothelioma 2.3% (n = 4), gastric adenocarcinoma 1.4% (n = 3), and others 1.4% (n = 2). One hundred fifty-six (71.2%) patients received neoadjuvant chemotherapy with a mean of 2.7 ± 3.19 neoadjuvant cycles received.
The intraoperative and postoperative parameters (Tables 2 and 3) were (i) operative time of 383.4 ± 113.3 min, (ii) 81/219 patients had a PCI higher than 20, (iii) 86/219 required a complete peritonectomy, (iv) 134 (61.2%) patients required intestinal resections, (v) optimal cytoreduction was obtained in 213 patients (97.3%), (vi), 36 (16.4%) patients required blood products transfusion during the procedure, (vii) 81 (37%) vasoactive drugs support, and (viii) a total of 175/219 patients had preserved diuresis during the intervention.
According to the Dindo-Clavien morbidity classification, 49/219 (22%) had major complications (grade 3–grade 5) during the first 30 days after surgery, and 68/219 (31%) had cumulative major morbidity within 90 days after surgery. The mean hospital stay was 12.1 ± 8.81 days.
The metabolic changes between the pre- and post-HIPEC included significant variations in blood levels of pH, lactic acid, sodium, potassium, glycemia, bicarbonate, and base excess (p < 0.05) (Table 4) (Fig. 1).
Comparative graph of means and standard deviation of metabolic parameters and temperature before HIPEC versus after HIPEC. A pH pre-HIPEC (7.34 ± 0.06) and post-HIPEC (7.32 ± 0.079 (p < 0.05). B Lactic acid (mmol/L) pre-HIPEC (1.68 ± 1.24) and post-HIPEC (3.72 ± 1.94) (p < 0.05). C Sodium (mEq/L) pre-HIPEC (138.08 ± 2.72) and post-HIPEC (137.68 ± 3.02) (p < 0.05). D Potassium (mEq/L) pre-HIPEC (3.57 ± 0.5) and post-HIPEC (3.28 ± 0.42) (p < 0.05). E Glycemia (mg/dL) pre-HIPEC (149.4 ± 44.79) and post-HIPEC (227.5 ± 50.16) (p < 0.05). F Bicarbonate (mmol/L) pre-HIPEC (23.25 ± 2.75) and post-HIPEC (21.3 ± 2.94) (p < 0.05). G Bases excess (mEq/L) pre-HIPEC (− 2.42 ± − 3.10) and post-HIPEC (− 4.49 ± 3.49) (p < 0.05). H Temperature (°C) pre-HIPEC (35.47 ± 0.83) and post-HIPEC (37.80 ± 0.79) (p < 0.05)
The comparison between the open vs. closed HIPEC technique showed an increase in temperature in favor of the closed technique (p < 0.05). No other significant metabolic changes were observed.
In the multivariate study, patient age, pre-HIPEC glycemia, and post-HIPEC potassium were identified as risk factors for major postoperative complications (Table 5). The area under the ROC curve = 0.718 (95% CI = 0.624 to 0.811) (Fig. 2) showing a higher probability to predict early major complications. The resulting logistic equation is Z = logit (p) = − 9.780 + age * 0.045 + 1.238 * potassium_posHIPEC + 0.012 * glycemia_preHIPEC.
ROC curve for early complications. Area under the ROC curve = 0.718 (95% CI = 0.624 to 0.811). We observed that in almost 72% of all possible pairs of subjects in which one has early major complications and the other does not, the model will assign a higher probability to the subject with early major complications. The resulting logistic equation is Z = logit (p) = − 9.780 + age * 0.045 + 1.238 * potassium_posHIPEC + 0.012 * glycemia_preHIPEC
Discussion
In recent years, the CRS + HIPEC has become a routine procedure performed on patients with peritoneal carcinomatosis. This procedure is considered a major surgery since it includes an aggressive surgical technique with HIPEC. HIPEC itself causes artificial ascites and an increase in body temperature causing important changes in internal homeostasis. As a prolonged surgical procedure, the patient experiences considerable blood and fluid losses, requiring specific management during the perioperative period [29,30,31]. In this sense, there is a lack of information about anesthetic management for these patients. Our study has shown the homeostatic changes and their effect on postoperative outcomes during CRS-HIPEC procedures.
Lactic acid is the end product of the energy pathway working without oxygen due to the impossibility of pyruvate formation under anaerobic conditions, and in other situations, the increase of lactic acid is related to metabolism [32]. The increase in lactic acid levels in patients who have undergone CRS + HIPEC may be due to different mechanisms: (i) the stromal cells, feeding the cancer cells with lactate [33, 34]; (ii) the long duration of the intervention; (iii) the state of peripheral hypoperfusion caused by the surgical aggressiveness and the blood loss; and (iv) the high blood glucose levels. The factors related to HIPEC include (i) the denaturation of serum proteins, (ii) the increasing of intra-abdominal pressure and metabolic requirements, (iii) the peripheral vasodilation due to the effect of hyperthermia, and (iv) the toxicity of the cytostatic used [35, 36].
It is also important to highlight the implication of the type of solution used to dilute the chemotherapeutic agents in the homeostatic changes. Several types of dilutions are used in different worldwide protocols including dextrose solutions or balanced electrolyte solutions [37]. In our protocol, chemotherapy is diluted in a 1.5% dextrose solution resulting in a decrease in sodium, potassium, and pH levels after the completion of HIPEC compared to previously reported using 5% glucose solutions [38]. These differences are probably related to less water reabsorption and less peritoneal electrolyte excretion [39]. Regarding the percentage of dextrose solution used, the increase in glycemia is also affected by surgical stress and resistance to insulin [40]. In this sense, the type of solution should be considered according to the patient’s characteristics [41, 42].
The use of HIPEC in a closed or open way is a controversial issue today, and they have not shown differences in terms of survival or morbidity [43]. When comparing both HIPEC techniques, the analysis of the metabolic parameters and temperature showed that the body temperature at the end of the closed technique was higher (p < 0.05) than the open HIPEC technique. Although we did not find significant metabolic changes in our study, a sustained increase in temperature may imply significant hemodynamic and metabolic changes, so strict temperature monitoring is recommended [43, 44].
The observed percentages of major postoperative morbidity (22%) are similar to those previously published by specialized centers [15, 45, 46]. Using the regression model, the variables age, post-HIPEC potassium, and pre-HIPEC blood glucose had a predictive value to detect postoperative major morbidity. Recent studies have failed to correlate intraoperative lactic acid levels with major postoperative morbidity [35]. Previous publications have provided different tools for predicting major morbidity, but they have not included any intraoperative metabolic changes [6, 7, 46, 47].
We are aware that our work has limitations that reduce the power of our conclusions. The first of these deals with all the limitations related to a retrospective study despite prospective data collection. However, this study represents the largest cohort studied for metabolic changes associated with HIPEC procedures.
Conclusion
The administration of HIPEC after cytoreductive intraperitoneal cancer surgery causes significant changes in internal homeostasis, particularly in the levels of lactic acid, blood glucose, and the patient’s temperature. The patient’s age, post-HIPEC potassium, and pre-HIPEC blood glucose levels are intraoperative predictive factors for major morbidity, and they must be controlled.
Change history
16 February 2023
A Correction to this paper has been published: https://doi.org/10.1007/s00423-023-02824-5
References
Sadeghi B, Arvieux C, Glehen O et al (2000) Peritoneal carcinomatosis from non-gynecologic malignancies. results of the EVOCAPE 1 Multicentric Prospective Study. Cancer 88:358–63
Sugarbaker PH (1995) Peritonectomy procedure. Ann Surg 221:29–42
Sugarbaker PH, Cunliffe W, Belliveau JF, DeBruijn EA, Graves T, Mullins R et al (1988) Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treat 1:66–79
Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40:256–260
Cochrane Database Syst. Rev. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev (11): CD005340. https://doi.org/10.1002/14651858.CD005340.pub3.
Arjona-Sanchez A, Muñoz-Casares FC, Casado-Adam A et al (2013) Outcome of patients with aggressive pseudomyxomaperitonei treated by cytoreductive surgery and intraperitoneal chemotherapy. World J Surg 37(6):1263–1270
Muñoz-Casares C, Medina-Fernández FJ, Arjona-Sánchez A et al (2016) Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: long-term outcomes and perspectives from a high-volume center. EJSO 42:224–233
Spiliotis J, Halkia E, Lianos E et al (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22:1570–1575
Jaaback K, Johnson N, Lawrie TA (2016) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (review). Cochrane Database Syst Rev 1:CD005340. https://doi.org/10.1002/14651858.CD005340.pub4
Yan TD, Black D, Savady R, Sugarbaker PH (2007) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomixoma peritonei. Ann Surg Oncol 14:484–492
Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:37–43
Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63–68
Yan TD, Welch L, Black D, Sugarbaker PH (2007) A systematic review on the efficacy of cytorreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18:827–834
Piche N, Leblond FA, Sideris L et al (2011) Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg 254(1):138–144
Chua C, Yan D, Saxena A, Morris D (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and primarily. Ann Surg 249:900–907
Foster JM, Sleightholm R, Patel A et al (2019) Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open 2(1):e186847. https://doi.org/10.1001/jamanetworkopen.2018.6847
Raspe C, Piso P, Wiesenack C, Bucher M (2012) Anesthetic management in patients undergoing hyperthermic chemotherapy. Anesth med dis 25:3
Raft J, Parisot M, Marchal F et al (2010) Impact of the hyperthermic intraperitoneal chemotherapy on the fluid-electrolytes changes and on the acid-base balance. Ann Fr Anesth Reanim 29(10):676–81. https://doi.org/10.1016/j.annfar.2010.06.021
De Somer F, Ceelen W, Delanghe J et al (2008) Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 28:61–66
Nguyen MK (2008) Lessons learned from hyponatremia associated with hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 28:32–34
Ceelen WP, Peeters M, Houtmeyers P, Breusegem C et al (2008) Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol 15(2):535–41
Arjona-Sánchez Á, Cadenas-Febres A, Cabrera-Bermon J et al (2016) Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances. EJSO 42:869–876
Jaquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J ExpClin Cancer Res 15:49–58
Sánchez-García S, Villarejo-Campos P, Padilla-Valverde D, Amo-Salas M, Martín-Fernández J (2016) Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-1.0 Combat): a clinical pilot study. Int J Hyperthermia 32(5):488–95
Miller TE, Myles PS (2019) Perioperative fluid therapy for major surgery. Anesthesiol 130:825–832
Harmon RL, Sugarbaker PH (2005) Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2:3. https://doi.org/10.1001/jamanetworkopen.2018.6847
Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
Rothfield KP, Crowley K (2012) Anesthesia considerations during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surg Oncol Clin N Am 21(4):533–541
Sugarbaker PH, Gianola FJ, Speyer JC et al (1985) Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surg 98:414–422
Leigh NL, Solomon D, Feingold D et al (2020) Improved survival with experience: a 10-year learning curve in hyperthermic intraperitoneal chemotherapy and cytoreductive surgery. Ann Surg Oncol 27(1):222–231
Fuller BM, Dellinger RP (2012) Lactate as a hemodynamic marker in the critically ill. Curr Opin Crit Care 18(3):267–272
Lu J, Tan M, Cai Q (2015) The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett 356(2 Pt A):156–164
Aneba CA, Bellance N, Yang L, Pabst L, Nagrath D (2021) Pyruvate uptake is increased in highly invasive ovarian cancer cells under anoikis conditions for anaplerosis, mitochondrial function, and migration. Am J Physiol Endocrinol Metab 303(8):E1036–E1052
Tonello M, Barina A, Turchet F et al (2020) Clinical and predictive value of blood lactate levels during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a comparative analysis. Updates Surg 2021 Feb 73(1):313–319
Miao N, Pingpank JF, Alexander HR, Royal R, Steinberg SM, Quezado MM et al (2009) Cytoreductive surgery and continuous hyperthermic. Peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic and anesthetic considerations. Ann Surg Oncol 16(2):334–44
Rueth NM, Murray SE, Huddleston SJ et al (2011) Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Ann Surg Oncol 18:174–180
Raft J et al (2010) Impact of the hyperthermic intraperitoneal chemotherapy on the fluid-electrolyte changes and on the acid-base balance. Annales Francaises d’Anesthesie et de Réanimation 29:676–681
De Somer F, Ceelen W, Delanghe J, De Smet D, Vanackere M, Pattyn P et al (2008) Severe hyponatremia, hyperglycemia, and hy- hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 28:61–66
Dexter SP, Vucevic M, Gibson J, McMahon MJ (1999) Hemodynamic consequences of high- and low- pressure capnoperitoneum during laparoscopic cholecystectomy. Surg Endosc 13:376–381
Schmidt C, Creutzenberg M (2008) Peri-operative anesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anesthesia 63:389–395
Bleiler D, Bleiler S, Sinner B (2018) Perioperatives Management im Rahmen der CRS und HIPEC. Chirurg 89:687–692
Nierhaus A, Meissner C, Hegewisch S et al (2000) Alterations of metabolic and hemodynamic parameters during whole body hyperthermia on the ICU. Crit Care 3:P200
Doyle JF, Schortgen F (2016) Should we treat pyrexia? And how do we do it? Crit Care 20:303
Chua TC, Moran BJ, Sugarbaker PH et al (2012) Early and long-term outcome data of patients with Pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol< 30(20):2449–2456
Elias D, Gilly F, Quenet F et al (2010) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 36:456–462
Baumgartner JM, Kwong TG et al (2015) A novel tool for predicting major complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2016 May 23(5):1609–17
Funding
Funding for open access publishing: Universidad de Córdoba/CBUA.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Rubio-López, J.D., Durán-Martínez, M., Moreno-Blázquez, A. et al. Intraoperative metabolic changes associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Langenbecks Arch Surg 408, 34 (2023). https://doi.org/10.1007/s00423-023-02770-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00423-023-02770-2